AR and posterior cortical atrophy: AR pathway inhibitors targeting the ligand-binding domain (enzalutamide (ENZ), apalutamide (APA), darolutamide (DARO)) and the de novo synthesis of androgens (abiraterone acetate (ABI)) have changed the treatment landscape across several PCa disease states.